Fulcrum Equity Management Amgen Inc Transaction History

Fulcrum Equity Management

$115 Million
Q3 2024

A detailed history of Fulcrum Equity Management transactions in Amgen Inc stock. As of the latest transaction made, Fulcrum Equity Management holds 1,988 shares of AMGN stock, worth $585,525. This represents 0.56% of its overall portfolio holdings.

Number of Shares

1,988

Previous 1,974 0.71%

Holding current value

$585,525

Previous $616,000 3.9%

% of portfolio

0.56%

Previous 0.57%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 21, 2024	BUY	$309.38 - $337.38 $4,331 - $4,723	14 Added 0.71%	1,988 $640,000
Q2 2024 Jul 19, 2024	BUY	$262.75 - $319.31 $16,027 - $19,477	61 Added 3.19%	1,974 $616,000
Q1 2024 Apr 24, 2024	BUY	$268.87 - $324.56 $14,518 - $17,526	54 Added 2.9%	1,913 $543,000
Q4 2023 Jan 18, 2024	SELL	$255.7 - $288.46 $36,309 - $40,961	-142 Reduced 7.1%	1,859 $535,000
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $1,749 - $2,171	8 Added 0.4%	2,001 $537,000
Q2 2023 Jul 07, 2023	BUY	$214.27 - $253.37 $79,065 - $93,493	369 Added 22.72%	1,993 $442,000
Q1 2023 Apr 06, 2023	BUY	$225.79 - $275.2 $103,863 - $126,592	460 Added 39.52%	1,624 $392,000
Q4 2022 Jul 07, 2023	SELL	$229.03 - $291.01 $189,865 - $241,247	-829 Reduced 41.6%	1,164 $305,000
Q4 2022 Jan 10, 2023	BUY	$229.03 - $291.01 $17,635 - $22,407	77 Added 7.08%	1,164 $0
Q3 2022 Oct 11, 2022	BUY	$224.46 - $253.15 $243,988 - $275,174	1,087 New	1,087 $245,000
Q1 2022 Apr 15, 2022	SELL	$219.27 - $242.57 $340,964 - $377,196	-1,555 Closed	0 $0
Q4 2021 Jan 25, 2022	SELL	$198.88 - $227.6 $5,767 - $6,600	-29 Reduced 1.83%	1,555 $350,000
Q3 2021 Jan 25, 2022	BUY	$212.27 - $248.7 $56,676 - $66,402	267 Added 20.27%	1,584 $337,000
Q2 2021 Jul 15, 2021	BUY	$233.58 - $259.14 $27,328 - $30,319	117 Added 9.75%	1,317 $321,000
Q1 2021 Apr 05, 2021	SELL	$221.91 - $258.6 $6,213 - $7,240	-28 Reduced 2.28%	1,200 $299,000
Q4 2020 Feb 22, 2021	SELL	$216.38 - $257.67 $36,135 - $43,030	-167 Reduced 11.97%	1,228 $282,000
Q3 2020 Oct 27, 2020	SELL	$234.65 - $260.95 $278,529 - $309,747	-1,187 Reduced 45.97%	1,395 $354,000
Q2 2020 Aug 17, 2020	BUY	$197.81 - $242.74 $93,168 - $114,330	471 Added 22.31%	2,582 $609,000
Q1 2020 Apr 01, 2020	SELL	$182.24 - $241.7 $99,320 - $131,726	-545 Reduced 20.52%	2,111 $428,000
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $17,218 - $22,131	-91 Reduced 3.31%	2,656 $640,000
Q3 2019 Nov 05, 2019	BUY	$174.11 - $208.62 $12,710 - $15,229	73 Added 2.73%	2,747 $531,000
Q2 2019 Aug 12, 2019	SELL	$166.7 - $195.41 $246,715 - $289,206	-1,480 Reduced 35.63%	2,674 $525,000
Q1 2019 May 03, 2019	BUY	$180.87 - $203.88 $1,085 - $1,223	6 Added 0.14%	4,154 $789,000
Q4 2018 Mar 05, 2019	BUY	$178.4 - $208.25 $740,003 - $863,821	4,148 New	4,148 $807,000

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulcrum Equity Management, based on Form 13F filings with the SEC.

News

Stay updated on Fulcrum Equity Management with notifications on news.

Account

Fulcrum Equity Management Amgen Inc Transaction History